Innovent Begins Pivotal Trial for PD-1/IL-2 Cancer Drug in China

Innovent Biologics has announced the dosing of the first patient in a pivotal registrational study for its investigational bispecific fusion protein, IBI363/TAK-928. This drug, which targets both PD-1 and IL-2 pathways, is being evaluated in combination with bevacizumab for patients with late-line advanced colorectal cancer in China.

The study is designed to assess the efficacy and safety of this novel combination therapy. IBI363/TAK-928 aims to enhance the anti-tumor immune response by engaging T-cells through the PD-1 pathway while simultaneously delivering IL-2 to promote immune cell proliferation. Bevacizumab, an established anti-angiogenic agent, is included to potentially improve drug delivery and efficacy within the tumor microenvironment.

Colorectal cancer remains a significant health challenge globally and in China. The initiation of this study addresses the need for new treatment options for patients who have progressed on or are intolerant to standard therapies. Innovent has a growing portfolio of oncology drugs approved in China, positioning it to potentially bring this new therapy to market.

With the first patient dosed, the study is now actively enrolling participants. The results from this registrational trial will be critical for potentially gaining regulatory approval for IBI363/TAK-928 and expanding treatment options for advanced colorectal cancer patients.